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Abstract
Background: The aim of the study was to investigate the in vivo efficacy of local and systemic
antibiotic prophylaxis in the prevention of Staphylococcus (S.) epidermidis graft infection in a rat
model and to evaluate the bacterial adherence to frequently used prosthetic graft materials.
Methods: Graft infections were established in the subcutaneous tissue of 120 male Wistar rats by
implantation of Dacron/ePTFE grafts followed by topical inoculation with 2 × 107 CFUs of clinical
isolate of methicillin-resistant S. epidermidis. Each of the graft series included a control group, one
contaminated group that did not receive any antibiotic prophylaxis, two contaminated groups that
received systemic prophylaxis with teicoplanin or levofloxacin and two contaminated groups that
received teicoplanin-soaked or levofloxacin-soaked grafts. The grafts were removed 7 days after
implantation and evaluated by quantitative culture.
Results: There was significant bacterial growth inhibition in the groups given systemic or local
prophylaxis (P < 0.05). Methicillin-resistant S. epidermidis had greater affinity to Dacron graft when
compared with ePTFE graft in the untreated contaminated groups (P < 0.05).
Conclusion: The study demonstrated that the usage of systemic or local prophylaxis and
preference of ePTFE graft can be useful in reducing the risk of vascular graft infections caused by
staphylococcal strains with high levels of resistance.
Background
One of the most feared complications of the use of a pros-
thetic material is the appearance of infection after implant
[1-5]. Graft infection often results in prolonged hospitali-
zation, organ failure, amputation and death [4,6,7]. The
causative organisms are predominantly S. auerus and S.
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at the time of graft insertion and the most frequent source
of infection is from staphylococci from the patient's skin
[3,4,9]. The most important strategies for the prevention
of prosthetic infection are asepsis and the perioperative
administration of systemic antibiotics [10-12]. Moreover,
in the case of vascular grafts, alternative methods such as
antimicrobials bound in high concentrations to prosthetic
grafts have been proposed [2,10,11,13].
However, the antibiotic usage should be guided by local
bacterial prevalence and sensitivities, remembering that
most infections are caused by staphylococci. Levofloxacin
is a fluoroquinolone with an enhanced activity against
gram-positive cocci [14,15]. Teicoplanin is a glycopeptide
antibiotic and has an excellent bactericidal activity against
penicillinase-producing and methicillin-resistant S. epi-
dermidis [16,17].
Synthetic vascular prostheses have been developed to sup-
plement the limited supply of native graft materials. But
they may act as a foreign body in the patient and may har-
bour bacteria which results in graft infection [18]. Vascu-
lar graft composition and construction have been shown
to influence bacterial adherence [3,19].
The aim of the present study was to investigate the in vivo
efficacy of local and systemic antibiotic prophylaxis in the
prevention of S. epidermidis graft infection in a rat model
and to evaluate the bacterial adherence to frequently used
prosthetic graft materials.
Methods
This study was carried out in the animal laboratory of our
institution. All animals received humane care in compli-
ance with Principles of Laboratory Animal Care, formulated
by the Guide for the Care and Use of Laboratory Animals, pre-
pared by the National Academy of Sciences [20]. This
study was also approved by the Pamukkale University
Animal Research Ethics Committee, Denizli, Turkey.
The strain of methicillin-resistant S. epidermidis used in
the present study was isolated from a clinical specimen
(graft infection) submitted for routine bacteriological
investigation. Identification of the clinical isolate was
determined by Gram staining, catalase reaction, tube
coagulation test and Api-staph test (biomérieux, Lyon,
France). Methicillin sensitivity was investigated by oxacil-
lin disk diffusion test [21]. Levofloxacin and teicoplanin
(both from Aventis Pharma) were diluted in accordance
with manifacturers' recommendations yielding 1 mg/ml
stock solution. Solutions of drugs were made fresh on the
day of assay.
One-hundred and twenty adult male Wistar rats (weight
range 300 to 350 g) were used in this study. The study
included two series composed of 6 groups for each of the
woven, gelatin-imregnated polyethyleneterephthalate
(Dacron) (Gelwave, Sulzer Vascutek) (D1–6) and
expanded polytetrafluoroethylene (ePTFE) (Alpha Graft®,
Alpha Research) (P1–6) grafts. Each of the series included
one group with no graft contamination and no antibiotic
prophylaxis (uncontaminated control, Dacron1, ePTFE1),
one contaminated group that did not receive any antibi-
otic prophylaxis (untreated control, Dacron2, ePTFE2),
one contaminated group that recieved teicoplanin-soaked
grafts (Dacron3, ePTFE3), one contaminated group in
which perioperative intraperitoneal prophylaxis with
teicoplanin (10 mg/kg) was administered (Dacron4,
ePTFE4), one contaminated group that recieved levo-
floxacin-soked grafts (Dacron5, ePTFE5) and one contam-
inated group in wich perioperative intraperitoneal
prophylaxis with levofloxacin (10 mg/kg) (Dacron6,
ePTFE6) was administered. Each rat was anesthetized with
a 2:1 mixture of kethamine hydrochloride (100 mg/ml)
(Pfizer):xylazine hydrochloride (20 mg/ml) (Bayer) at a
dose of 0.75 ml/kg intramuscularly. Rats' hair of the back
was shaved and the skin was cleaned with 10% povidone-
iodine solution. One subcutaneous pocket was made on
each side of the median line by a 1.5 cm incision. Asepti-
cally, 1-cm2 sterile collagen-sealed Dacron or ePTFE grafts
were implanted into the pockets. Prior to implantation, in
the groups Dacron3, ePTFE3 and Dacron5, ePTFE5 the
Dacron and ePTFE graft segments were impregnated with
1 mg/ml teicoplanin and levofloxacin, respectively. Anti-
biotic bonding was obtained immediately before implan-
tation by soaking grafts for 20 minutes in a sterile solution
of antibiotic. The effect of preoperative intraperitoneal
teicoplanin and levofloxacin administered 30 minutes
before implantation at the standard dose of 10 mg/kg was
evalueted in the groups Dacron4, ePTFE4 and Dacron6,
ePTFE6, respectively. The pockets were closed by means of
skin clips and sterile saline solution (1 ml) containing
methicillin-resistant strain S.epidermidis at a concentration
of 2 × 107 CFUs/ml was inoculated onto the graft surface
by using a tuberculin syringe to create a subcutaneous
fluid-filled pocket. The animals were returned to individ-
ual cages and thoroughly examined daily. All grafts were
removed 7 days following implantation.
The explanted grafts were placed in sterile tubes, washed
in sterile saline solution, placed in tubes containing 10 ml
of phosphate-buffered saline solution and sonicated for 5
minutes to remove the adherent bacteria from the grafts.
Quantitation of viable bacteria was performed by cultur-
ing serial dilutions (0.1 ml) of the bacterial suspension on
blood agar plates. All plates were incubated at 37°C for 48
hours and evaluated for the presence of the staphylococcalPage 2 of 6
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number of colony-forming units (CFUs) per plate.
Quantitative culture results were presented as arithmetic
mean ± standard deviation (S.D.). Differences among the
groups were evaluated using one-way analysis of variance
(ANOVA), and multiple comparisons between the groups
were performed with a posthoc test (Tukey's HSD test).
Differences were considered statistically significant when
P < 0.05. Data were analyzed by a statistical software
(SPSS for Windows 11.0; SPSS, Chicago, Illinois).
Results
None of the animals included in any group died or had
clinical evidence of drug related adverse effects, such as
local signs of perigraft inflammation, anorexia, vomiting,
diarrhoea, and behavioural alterations.
There was no anatomic and microbiological evidence of
graft infection in the animals included in the uncontami-
nated control groups. In contrast, all 20 rats included in
the untreated contaminated control groups (Dacron2 and
ePTFE2) demonstrated evidence of graft infection, with
quantitative culture results showing 3.7 × 107 ± 1.1 × 107
CFU/ml and 5.3 × 106 ± 2.4 × 106 CFU/ml, respectively.
The quantitative graft cultures of the other groups demon-
strated bacterial growth in different counts. The results are
summarised in Table 1.
The amount of bacterial growth was statistically signifi-
cantly higher in untreated contaminated Dacron-group
(Dacron2) when compared to the other groups (P < 0.05).
The second highest bacterial growth was observed in
untreated contaminated ePTFE-group (ePTFE2) and it was
also significantly different from all antibiotic-treated
groups, except levofloxacin-bonded Dacron (Dacron5)
and ePTFE (ePTFE5) groups (P < 0.05). Although the
highest reduction in bacterial growth number was
observed in the intraperitoneal teicoplanin groups
(Dacron4 and ePTFE4), there was no statistically signifi-
cant difference among the treated contaminated groups (P
> 0.05).
Discussion
Various studies have demonstrated that systemic antibi-
otic prophylaxis reduces the incidence of prosthetic vascu-
lar graft infections, but not completely prevent them [22-
24]. That's because antibiotic impregnated grafts are
arousing interest as they can deliver antibiotic at the time
that the graft is at the greatest risk of contamination [22].
In vascular surgery, S. epidermidis has been shown to be
the leading isolate with infection appearing late after
implantation [3,25,26]. So, in order to simulate the clini-
cal setting, we preferred to use an isolate of S. epidermidis
which was obtained from an infected vascular conduit in
our hospital.
Teicoplanin and levofloxacin are attractive options for
local and systemic antibiotic prophylaxis in preventing S.
epidermidis graft infections, because they are effective anti-
biotics against coagulase positive and negative staphylo-
cocci [23,27]. Teicoplanin is used parenterally to treat
infections caused by staphylococcal infections since the
Table 1: Quantitative microbiological results of the in vivo experiments.
Groupa Graft-bonded drugb Intraperitoneal preoperative drugc Quantitative graft culture (CFUs/
ml)
Dacron 1d,e -- -- 0.0
Dacron 2 -- -- 3.7 × 107 ± 1.1 × 107
Dacron 3d,e Teicoplanin -- 5.6 × 103 ± 1.2 × 103
Dacron 4d,e -- Teicoplanin 5.3 × 102 ± 1.2 × 102
Dacron 5d Levofloxacin -- 4.0 × 105 ± 5.5 × 104
Dacron 6d,e -- Levofloxacin 4.9 × 104 ± 4.7 × 103
ePTFE 1d,e -- -- 0.0
ePTFE 2d -- -- 5.3 × 106 ± 2.4 × 106
ePTFE 3d,e Teicoplanin -- 4.7 × 103 ± 1.2 × 103
ePTFE 4d,e -- Teicoplanin 4.2 × 102 ± 1.4 × 102
ePTFE 5d Levofloxacin -- 3.7 × 105 ± 2.8 × 104
ePTFE 6d,e -- Levofloxacin 4.7 × 104 ± 4.1 × 103
a Each group was performed by 10 animals; Dacron1–6, groups of animals by implantation of Dacron protheses; ePTFE1–6, groups of animals by 
implantation of ePTFE protheses.
b Graft segments were impregnated with 1 mg/ml teicoplanin; 1 mg/ml levofloxacin.
c Teicoplanin 10 mg/kg, levofloxacin 10 mg/kg.
d Statistically significant when compared with group Dacron2
e Statistically significant when compared with group ePTFE2Page 3 of 6
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Recently, teicoplanin has been administered as periopera-
tive antibiotic prophylaxis [29-31]. Teicoplanin has a long
half-life and good tissue and bone penetration [32]. In an
earlier study at St James's University Hospital, teicoplanin
exhibited good penetration into ischaemic tissue, which
may be desirable for prophylaxis in vascular surgery [33].
Kester et al. [34] concluded from a two-centre study that a
single dose of teicoplanin showed similar efficacy to a
three-dose regimen of cephradine plus metronidazole as
prophylaxis for wound infection in vascular surgery. It
was showed that levofloxacin had greater in vitro and in
vivo anti-staphylococcal activity than the other fluoroqui-
nolones such as ofloxacin or ciprofloxacin [35-37]. In pre-
vious studies levofloxacin was reported to reach high
concentrations in serum and various tissues, following
single dose levofloxacin administration [38,39]. In the
present study it was found that both local and systemic
levofloxacin usage reduced bacterial count in the graft seg-
ments when compared to untreated contaminated con-
trols (Dacron2 and ePTFE2) . Although it was not
statistically significant, systemic usage of levofloxacin was
more effective than the local one. However, interestingly,
the reducing efficacy of local usage of levofloxacin on bac-
terial count was also inadequate to reach a statistical dif-
ference when compared to untreated contaminated ePTFE
graft (ePTFE2) (P > 0.05).
The question remains whether local or systemic antibiotic
prophylaxis is the best choice for reducing the risk of pros-
thetic vascular graft infection. When a local prophylaxis is
used, the dose of antibiotic delivered to the operative site
could be important in eliminating infections, as most of
them are due to contamination at the time of implanta-
tion. Simple soaking in an antibiotic solution immedi-
ately prior to implantation is an easy way of impregnating
the prosthetic graft that can be done extemporaneously by
the surgeon himself. But during this procedure the risk of
contamination of the graft increases.
Antibiotics having good activity against gram-positive
bacteria were used in bonding vascular grafts in experi-
mental models. Hernandez-Richter et al. [40] found that
rifampicin and triclosan but not silver was effective in pre-
venting bacterial infection of vascular Dacron graft mate-
rial. Giacometti et al. [41] confirmed the efficacy of
mupirocin-soaked grafts against methicillin-susceptible,
methicillin-resistant and vancomycin-intermediate S. epi-
demidis. Ghiselli et al. [42] showed that Temporin A had
an antibacterial in vitro activity against methicillin-sus-
ceptible and methicillin-resistant S. epidermidis. Efficacy of
polycationic peptides in preventing vascular graft infec-
tion due to methicillin-resistant S. aureus with intermedi-
ate resistance to glycopeptides was demonstrated to be
very good [11]. Dell'Acqua et al. [43] suggested that
RNAIII-inhibiting peptide (YSPWTNF-NH2), applied
locally and systemically, can completely inhibit drug-
resistant S. aureus and S. epidermidis biofilms. Osada et al.
[44] demostrated that levofloxacin incorporated into
albumin-sealed Dacron graft had a bactericidal action and
adhesive prevention against inoculated S. aureus in a graft
model.
Soaking of the grafts in solutions of 1 mg/ml of different
antibiotics has been shown to be effective in making anti-
biotic-bonding drugs [45]. Previously, Levofloxacin and
teicoplanin, used in 10 mg/kg consantration have been
shown to be successful in reducing the risk of prosthetic
graft infection [23]. We chosed the same concentrations
for the each antibiotic in our model according to these
studies' findings.
Our data indicate that, although the difference was not
statistically significant, local usage of teicoplanin more
effectively reduces the bacterial count in graft segments
than the local levofloxacin application and it seems to be
the most appropriate antibiotic for local vascular graft
prophylaxis. The finding that antibiotic-impregnated
grafts alone can not prevent prosthetic vascular graft infec-
tion is similar to the results found by other groups
[11,22]. The combined usage of systemic antibiotic
prophylaxis and drug-bonded grafts has been shown to be
more effective in decreasing the incidence of prosthetic
vascular graft infections [10,23]. But this combination
may have disadvantages like increased intraoperatif con-
tamination risk and cost.
The results of this study demonstrated that both systemic
and local prophylactic antibiotic treatment was useful.
Although, the difference was not significant, the highest
reduction in bacterial number was in the intraperitoneal
teicoplanin groups in our study and this finding is parallel
with previous studies, [23,37]. Second reason for choos-
ing teicoplanin was its advantage as single dose applica-
tion. This is certainly more desirable than frequent dosing
required by conventional systemic antibiotics or other
glycopeptides.
All kinds of prosthetic vascular grafts are susceptible in
varying degrees to infection via direct contamination dur-
ing implantation or bacteremia after operation. Dacron
and ePTFE are the most frequently used materials. Surface
area and molecular structure differs between the two types
of grafts. Graft material of ePTFE is relatively nonporous
when it is compared with multifilamented Dacron grafts.
EPTFE is more hydrophobic than Dacron, perhaps that's
why it is less likely to form bonds with those bacteria in
which the cell walls have hydrophobic properties [19,46].
The findings of the present study was similar with previ-
ous studies reporting that S. epidermidis, S. aureus andPage 4 of 6
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compared with ePTFE [19,47,48]. The bacterial count in
the untreated contaminated ePTFE grafts was very low
than the untreated contaminated Dacron groups.
Untreated contaminated ePTFE graft was found to be
almost as effective as levofloxacin-bonded Dacron and
ePTFE grafts. Although there were not statistical signiffi-
cant differences among the treated contaminated groups,
it was observed that bacterial growth was more in Dacron
grafts. This finding may be of a clinical importance and
may influence the choice of a surgeon when he has to pre-
fer one of these grafts.
Further animal studies are needed to assess the efficacy of
commercially available grafts soaked in various antibiotic
solutions, against infections after sequental bacterial seed-
ing for up 7 days. Additionally, these results have to be
compared with the real situation of an implanted graft in
a living human being. It should not be forgotten that anti-
biotic/antiseptic impregnation is not the only way of pro-
tecting synthetic grafts. Modifying the surface
characteristics of prosthetic graft to minimise bacterial
adherence needs to be investigated further.
Conclusion
The study demonstrated that the usage of systemic or local
prophylaxis and preference of ePTFE graft can be useful in
reducing the risk of vascular graft infections caused by sta-
phylococcal strains with high levels of resistance.
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